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The West Health Policy Center is focused on research and education to identify innovations
and policy solutions that can slow the trajectory of rising healthcare costs while improving
access to? and the quality of? care, particularly for our nation?s growing population of
seniors. Specific areas of focus include reducing growth in U.S. spending on prescription
drugs, promoting value-based care models, increasing price transparency, and limiting
consumer exposure to high out-of-pocket costs. Solely funded by philanthropists Gary and
Mary West, the Policy Center is based in Washington, D.C., and is part of West Health, a
family of nonpartisan, nonprofit organizations dedicated to lowering the cost of healthcare
to enable successful aging. For more information visit https://www.westhealth.org/ or follow
us on Twitter @WestHealth.

CIDSA, the Council for Informed Drug Spending Analysis, is a nonpartisan expert group
funded by West Health and focused on bringing a non-pharma perspective to drug
spending policy dialogue. Learn more at www.cidsa.org and on Twitter at @CIDSAexperts.
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Int roduct ion
The pharmaceut ical indust ry has long argued t hat high drug prices ref lect t he high cost of innovat ion
and t hat reducing drug prices would necessarily slow t he pipeline of new drugs. These argument s have
been bolstered by st udies of large pharmaceut ical companies showing st at ist ical associat ions bet ween
t he projected market size or revenue for pharmaceut ical product s and research & development (R& D)
act ivit y. Our analysis recognizes t he increasingly import ant role of small biopharmaceut icals in drug
development , companies t hat t ypically have lit t le revenue and negat ive earnings, but are now
responsible for more t han 40 % of new drug approvals.

Any negative impact of drug price reductions on the
pipeline of pharmaceutical innovation may be
mitigated through strategic allocation of cost
reductions by large pharmaceutical companies.
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We examine t he relat ionship bet ween changes in revenue and R& D for companies of dif ferent size
f rom 20 0 0 -20 18 . W hile changes in R& D expense correlate wit h changes in revenue for t he largest
biopharmaceut ical companies (>$7B market cap), no such relat ionship is found for smaller companies.
Modeling t he impact of dif ferent ial cost reduct ions on t he pipeline of new product s, we f ind t hat any
negat ive impact of drug price reduct ions may be mit igated t hrough st rategic allocat ion of cost
reduct ions by large companies to dif ferent st ages of clinical development .
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Back ground
A f lurry of legislat ive act ivit y in t he 117t h Congress is aimed at reducing drug prices to ensure t hat
essent ial medicines for prevent ing and t reat ing disease are af fordable to all Americans.1 One of t he
major concerns about such legislat ion is t hat reducing drug prices would necessarily lead to reduced
invest ment in indust ry spending on research and development (R& D) and slow t he pipeline of
innovat ive, new t reat ment s for current ly int ract able diseases.

This concern was bolstered by an April 20 21 report f rom t he Congressional Budget Of f ice (CBO) t it led
Research and Development in t he Pharmaceut ical Indust ry, which considered t he impact of legislat ion
int roduced in t he 116 t h Congress t hat would have aut horized t he Secret ary of Healt h and Human
Services to negot iate drug prices paid by Medicare or Medicaid.2 The CBO concluded t hat ?The
prospect of such lower revenues would make invest ment s in R& D less at t ract ive to pharmaceut ical
companies? ? and t hat ?? approximately 8 fewer drugs would be int roduced to t he U.S. market over t he
20 20 ?20 29 period and about 30 fewer drugs over t he subsequent 10 years.?

The CBO?s f indings are not unprecedented. A series of papers by Vernon and colleagues examined t he
f inances of t he pharmaceut ical indust ry f rom 19 9 3-19 9 4, years t hat t he Clinton Healt h Plan was being
REDUCING
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years t hat t he Clinton plan was being debated, t hen experienced a (slow) rebound af ter t he Clinton
proposals were rejected.3 A complement ary dynamic has been observed in response to exogenous
f actors t hat increase t he market for pharmaceut ical product s such as demographic changes in t he US
populat ion4 and passage of Medicare Part D.5 Bot h f actors have been shown to be associated wit h
increased R& D spending and clinical t rial act ivit y specif ically in t herapeut ic areas most impacted by
ant icipated changes in market size.

These observat ions are consistent wit h a f inancialized view of t he biopharmaceut ical indust ry, which
posit s t hat t he allocat ion of resources to R& D is driven by t he projected revenue f rom product sales
and ret urn on invest ment .6 In t his context , product pricing and t he size of t he available market are
considered to be t he primary determinant s of R& D spending. A corollary to t his view of t he indust ry is
t hat , f aced wit h declining revenue or lower project ions of f ut ure revenue, companies would choose to
reduce invest ment s in R& D and priorit ize t heir prof it abilit y, rat her t han develop new product s wit h
lower prof it margins or ret urns on invest ment .
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Is reducing R& D an inevit able response t o lowering drug
prices?
Ot her analyses, however, have quest ioned t he assumpt ion t hat pharmaceut ical companies would
choose to reduce R& D spending to ensure prof it abilit y. A 20 19 white paper f rom t he West Healt h
Policy Center and Johns Hopkins Bloomberg School of Public Healt h examined t he prof it abilit y of a set
of 23 large pharmaceut ical companies, measured by ret urn on invested capit al (ROIC), f rom 20 11-20 19
compared to companies in ot her indust rial sectors. The analysis concluded t hat large pharmaceut ical
companies had signif icant ly higher ROIC t han companies and ot her sectors, and t hat ?? large
pharmaceut ical manuf act urers could endure signif icant revenue reduct ions, including t he reduct ions
considered in recent legislat ive proposals, while maint aining current research invest ment s and st ill
achieve t he highest ret urns of any market sector.?7 They concluded t hat capit al invest ment s by large
pharmaceut ical companies would remain more at t ract ive t han alternat ive invest ment s despite
subst ant ial reduct ions in drug prices and t he associated revenue. They concluded t hat ?W hile we
recognize t hat any reduct ion in revenues will change a company?s operat ional st rategy, we f ind t hat
large pharmaceut ical companies would st ill maint ain indust ry-leading ret urns on capit al.?

Analogous result s were described in a 20 20 st udy f rom t he Center for Integrat ion of Science and
WILL REDUCING DRUG PRICES SLOW INNOVATION

Indust ry at Bent ley Universit y. This st udy demonst rated t hat t he prof it s of 35 large pharmaceut ical
companies, measured by net income (earnings), were signif icant ly larger t han t hose of ot her
companies in t he S& P50 0 f rom 20 0 0 -20 18 ,8 t hough t he dif ference was part ly accounted for by
cont rolling for company size, year, and involvement in R& D. This st udy also highlighted t he scale of
pharmaceut ical revenue, prof it , and spending, showing t hat f rom 20 10 -20 18 , t hese companies
reported cumulat ive revenue of $11.5 t rillion and net income of $1.9 t rillion, while expensing $1.8 t rillion
for R& D and dist ribut ing $1.8 t rillion to shareholders in t he form of dividends or stock buybacks. This
st udy showed t hat large pharmaceut ical companies have t he capacit y to absorb subst ant ial reduct ions
in revenue wit hout compromising t he resources necessary to sust ain R& D and earnings comparable to
ot her leading indust rial sectors.
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The growing impact of small biopharmaceut ical companies
The present analysis recognizes t he increasingly import ant role of small biopharmaceut icals in drug
development . A 20 20 report f rom IQVIA noted t hat , while large pharmaceut ical companies
t radit ionally played t he dominant role in late-st age development and market ing of pharmaceut ical
product s, t his dynamic has changed over t he past decade.9 The report showed t hat f rom 20 16 -20 20 ,
approximately 40 % of new product s were bot h originated and launched by emerging
biopharmaceut ical companies, def ined by IQVIA as revenue <$50 0 million and R& D spending <$20 0
million. Anot her 20 % of new product s arose f rom development programs init iated by emerging
companies, but were launched af ter licensing or acquisit ion by est ablished f irms. This is not ably
dif ferent t han t he sit uat ion f rom 20 11-20 15, when less t han 20 % of new product s were launched by
emerging biopharmaceut ical companies.

Previous studies have erred by considering only
the impact of price reductions on the largest
pharmaceutical companies.
WILL REDUCING DRUG PRICES SLOW INNOVATION

The f inances of small biotechnology companies are dramat ically dif ferent f rom t hose of est ablished
f irms. A recent st udy examined t he f inancial performance and late-st age product development
pipelines of t he 319 biotechnology companies t hat had Init ial Public Of ferings (IPOs) on NASDAQ f rom
19 9 7-20 16 .10 This cohort of emerging, public biotechnology companies reported sust ained R& D
spending t hroughout t he st udy period and cont ributed to t he late-st age development of 144 new
product s, including 78 New Molecular Ent it ies (NMEs) and 34 f irst -in-class drugs, despite also
report ing lit t le revenue and consistent ly negat ive earnings. Nevert heless, t hese companies achieved
growt h of market capit alizat ion and shareholder value similar to t hat of a matched set of
non-biotechnology companies wit h concurrent IPO dates.

The st rategic role of R& D spending in small biotechnology companies is of ten dif ferent t han in larger
companies. Many early and emerging biopharmaceut ical companies have a science-based business
model, where t he ret urn on invest ment is predicated on increasing t he value of it s intellect ual propert y
and a variet y of potent ial applicat ions, rat her t han t he projected ret urns f rom a specif ic product wit h a
delimited market .11 Moreover, many companies are founded explicit ly to advance a specif ic technology
or cure for a part icular disease ent it y, and allocate t heir R& D spending to maximize t hese
opport unit ies. Thus, t he relat ionship bet ween revenue and R& D spending may not be t he same in
emerging, small public biotechnology companies as in large, est ablished pharmaceut ical companies.
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Relat ionship bet ween revenue and R& D f or companies of
dif f erent size
This analysis considered t he relat ionship bet ween revenue and R& D expense for all publicly t raded
biopharmaceut ical companies for t he years 20 0 0 -20 18 .12 The dat aset comprises 1379 companies and
10 ,0 35 f iscal years of reported f inancial dat a (see At t achment s). W hen considering t he ent ire dat aset ,
t here was a st rong associat ion bet ween annual revenue and R& D expense (Figure 1).

Examining t he relat ionship bet ween revenue and R& D in more det ail, we considered t he relat ionship
bet ween revenue and R& D separately for large pharmaceut ical companies, def ined as having a market
capit alizat ion >$7 billion, and small biopharmaceut ical companies, def ined as having a market
capit alizat ion <$7 billion. For large companies, t he f ract ion of revenue expensed as R& D, of ten referred
to as ?R& D intensit y,? was found to be relat ively const ant (Figure 2), wit h a median value of 16 .6 % (IQR
12.9 %-21.6 %).13 Furt her segment ing large companies into quart iles by t heir market capit alizat ion, t he
f ract ion of revenue expensed as R& D is most consistent for t he largest companies (2nd, 3rd, 4t h
quart iles) (Figure 2). In cont rast , t he f ract ion of revenue expensed as R& D varies widely for smaller
companies wit h a market capit alizat ion <$7 billion.
Fi g u r e 1:
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12

Company Size
Small (Mkt Cap < $7B)
Large (1st Quart ile)

9
R& D ($, billions)

Large (2nd Quart ile)
Large (3rd Quart ile)
Large (4t h Quart ile)

6

3

0
0

20

40

60

80

Revenue ($, billions)
Relat ionship bet ween annual revenue and R& D expense for 1,379 public biopharmaceut ical companies 20 10 -20 18 . Company size is
indicat ed for companies wit h market capit alizat ion <$7 billion (?small companies?) and companies wit h market capit alizat ion >$7 billion
(?large companies?) separat ed by quart ile f rom larger (4 t h quart ile) t o smaller (1st quart ile.) Each point represent s one f iscal year of dat a for
one company.
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Fi g u r e 2 :

Company Size
R& D/revenue (R& D intensit y)

10 ,0 0 0
Small (Mkt Cap < $7B)
Large (1st Quart ile)
Large (2nd Quart ile)

10 0

Large (3rd Quart ile)
Large (4t h Quart ile)
1

.0 1

0

10 0

20 0

30 0

40 0

Market capit alizat ion ($, billions)

Relat ionship bet ween market capit alizat ion and t he f ract ion of revenue expensed as R& D (R& D intensit y) for 1,379 public biopharmaceut ical
companies 20 10 -20 18 . Each point represent s one f iscal year of dat a for one company. INSERT shows t he dist inct ly dif ferent pat tern for large
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companies (market capit alizat ion >$7
billion)
and small companies
(marketSLOW
capit alizat
ion <$7 billion). The larger f igure separates large
companies by quart ile wit h t he largest companies represented in quart ile 4.

The relat ionship bet ween year-to-year changes in revenue and changes in R& D for large
pharmaceut ical companies is shown in Figure 3. There was signif icant posit ive associat ion bet ween
changes in revenue and changes in R& D for large companies (Figure 2, INSERT). This associat ion was
signif icant for companies in t he t hree largest quart iles (2nd, 3rd, 4t h quart iles), but not for companies
in t he lowest quart ile (1st quart ile) (Figure 2). The slope of t he t rendlines ref lect s t he change in R& D
expense associated wit h change in revenue for large companies in t he 2nd, 3rd, or 4t h quart iles.
Specif ically, for t hese companies, reduct ions of revenue up to 10 % were associated wit h reduct ion in
R& D spending up to 8 %.
There was also no signif icant associat ion bet ween changes in revenue and changes in R& D for smaller
companies wit h market capit alizat ion <$7 billion (not shown). No change in R& D would be expected for
reduct ions in revenue of up to 10 % in small companies wit h market capit alizat ion <$7 billion.
This analysis is consistent wit h previous st udies t hat described an associat ion bet ween revenue and
R& D spending in large pharmaceut ical companies. Extending t his analysis to all publicly t raded
biopharmaceut ical companies however, f urt her demonst rated t hat t here is no evidence for an
associat ion bet ween revenue and R& D spending for companies wit h market capit alizat ion <$7 billion.
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Fi g u r e 3 :

Company Size

20 0

Large (1st Quart ile)
Year to year change in R& D (%)

150

Large (2nd Quart ile)
Large (3rd Quart ile)

10 0

Large (4t h Quart ile)

50

0

-50
-10 0

0

10 0

20 0

Year to year change in revenue (%)

Relat ionship bet ween year-to-year changes in revenue and year to year changes in R& D for companies wit h market capit alizat ion >$7
billion 20 10 -20 18 . Each point represent s one f iscal year of dat a for one company.
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Unlike large pharmaceut ical companies, which are responsible for market ing t he large majorit y of
pharmaceut ical product s and t herefore generate t he majorit y of pharmaceut ical revenue, smaller
biopharmaceut ical companies are largely dependent on equit y invest ment s by public and private
investors14 , as well as part nerships wit h large pharmaceut ical companies, for operat ing capit al.

There is no evidence for an association between revenue
and R&D expense for biopharmaceutical companies with
market capitalization <$7 billion (2010-2018).
To assess t he relat ionship bet ween R& D spending and t he capit al available to small companies in a
given f iscal year, we examined t he relat ionship bet ween R& D expense and t he sum of cash and
short -term invest ment s at t he beginning of t he f iscal year, revenue, and sale of common and preferred
stock.15 W hen considering only companies wit h market capit alizat ion <$7 billion, we observed no
signif icant associat ion bet ween R& D expense and t his est imate of available capit al. W hile addit ional
st udies of t he relat ionship bet ween t he availabilit y of capit al and R& D spending in smaller companies
is warranted, t his analysis does not support t he assumpt ion t hat R& D spending in t hese companies
would be decreased in response to a reduct ion in drug prices.
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Cont ribut ions of large and small companies t o development
To assess t he dif ferent ial cont ribut ion of large and small biopharmaceut ical companies to t he drug
development pipeline, we examined clinical t rials listed in ClinicalTrials.gov.16 We ident if ied phase 1,
phase 2, and phase 3 clinical t rials init iated f rom 20 10 -20 19 wit h at least one corporate sponsor.
Clinical t rials sponsored by companies wit h market capit alizat ion >$7 billion at any t ime during t he
st udy period were considered to have been sponsored by ?large companies? and were categorized by
t he highest quart ile achieved by t hat company.
Fi g u r e 4 :
10 0 %

Company Size

% t rials in ClinicalTrials.gov

Small (Mkt Cap < $7B)
Large (1st Quart ile)

75%

Large (2nd Quart ile)
Large (3rd Quart ile)
Large (4t h Quart ile)
50 %

25%
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0%
Phrase 1

Phrase 2

Phrase 3

Fract ion of clinical t rials sponsored by companies wit h market capit alizat ion <$7 billion (small companies) or companies
wit h market capit alizat ion >$7 billion (large companies) separated by quart ile. Dat a f rom ClinicalTrial.gov.

Ot her corporate clinical t rials were categorized as small companies. Small companies include public
companies wit h market capit alizat ion <$7 billion t hroughout t he st udy period as well as companies not
ident if ied by GICS codes or included in Compust at . For clinical t rials wit h mult iple sponsors, t rials were
categorized by t he category of t he largest sponsor. The result s are illust rated in Figure 4.

Companies with market capitalization <$7 billion sponsor the
majority (~60%) of phase 1, phase 2, and phase 3 clinical trials
of new pharmaceuticals.
This analysis suggest s t hat approximately 6 0 % of phase 1, phase 2, and phase 3 clinical t rials f rom
20 10 -20 19 were sponsored by small biopharmaceut ical companies wit h market capit alizat ions <$7
billion. These dat a are consistent wit h t he observat ion by IQVIA t hat small companies, def ined as
having revenue <$50 0 M, account for 70 % of product s in phase 3 t rials.17

W ILL REDUCING DRUG PRICES SLOW INNOVATION l 11

M odeling t he impact of revenue reduct ions on new drug
approvals
Assuming revenue-related reduct ion in R& D spending will impact invest ment in phased clinical t rials,
t he progression of candidate t herapeut ics is modeled t hrough t he development pipeline. The model
assumes t hat companies of dif ferent size will reduce R& D spending by dif ferent amount s and t hat cost
reduct ion are achieved by select ive allocat ion of resources to t he t hree phases of clinical development .
The model incorporates published dat a regarding t he per drug cost s of each clinical phase as well as
t he phase t ransit ion success rate.18 The model incorporates changes in R& D spending proport ional to
reduct ion in revenue for companies of dif ferent size and t he f ract ion of clinical t rials performed by
small companies as shown:

a%

Percent age of t rials by small companies

Company size

Change in R& D a,19

Phase 1

Phase 2

Phase 3

Smallb

n/ad

59 .8 %

6 0 .1

56 .7

Largec
Q1
Q2
Q3
Q4

0 .3%
0 .8 6 %
1.0 6 %
0 .9 5%

1.2%
2.1%
14.2%
22.7%

1.5%
3.0 %
12.0 %
23.4%

1.7%
3.2%
12.7%
25.7%

b Small companies have market capit alizat ion <$7 billion; c Large companies have market
change in R& D for each 1% reduct ion in WILL
revenue;
REDUCING
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capit alizat ion >$7 billion and are separat ed by quart ile; d No change in R& D expense is ant icipat ed for companies wit h market capit alizat ion <$7 billion.

A schemat ic of t he model is shown in Figure 5. The model est imates t he steady st ate level of drug
approvals for a hypot het ical number of candidate product s entering clinical development . The model
enables considerat ion of scenarios t hat embody dif ferent levels of revenue reduct ion and dif ferent ial
allocat ion of cost savings bet ween phase 1, phase 2, and phase 3 clinical t rials.

Several aspect s of t his model should be emphasized. First , t he model assumes t hat all companies are
subject to a 10 % decrease in revenue, regardless of size. Second, t he model assumes no change in t he
number of new product s proceeding t hrough clinical t rials sponsored by small companies. Third,
reported t ransit ional success rates bet ween phases commonly conf late technical f ailures related to
safet y or ef f icacy, wit h ?commercial f ailures? t hat result in discont inuat ion of a candidate product due
to economic considerat ions, corporate st rategy, product priorit izat ion, or inadequate f unding. The
commercial f ailure rate for product s in development is est imated to be as high as 20 -30 %.20 The
model assumes t hat t he cost savings required to reduce R& D spending will be realized by reducing t he
number of drugs t ransit ioning to t he next phase of clinical development , ef fect ively increasing t he
commercial f ailure rate f rom t hat phase. Cost reduct ions may also decrease t he commercial f ailure
rate (and increase t he success rate in a specif ic phase) by reducing t he number of product s available to
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Fi g u r e 5 :
enter t hat phase relat ive to t he decrease in
spending.
% change in revenue
rat io: % change revenue
to % change R& D by
company size

Figure 6 shows t he drug approvals for a baseline
case and t hree scenarios where pharmaceut ical
revenue is decreased by 10 %. The baseline case

% change in R& D by
company size
hypot het ical number
of drugs entering
pipeline

assumes t hat 40 0 candidate compounds enter
phase 1 t rials in a t ypical year. Based on
reported success rates, 47 of t he 40 0 candidate
compounds would be

approved.21 The

baseline success rate,
# drug approval

10 %

reduct ion in global pharmaceut ical revenue
modeled in t his scenario represent s

change in phase
t ransit ion success rate
(commercial factors)

approximately a 21% reduct ion in prices for
branded pharmaceut icals in t he US market . This
est imate is based on branded pharmaceut icals

overall success rate,
# drug approvals

historical phase
t ransit ion success rates
(technical & commercial
factors)

st rategic allocat ion of
cost reduct ion across
clinical phases

represent ing 8 8 % of US drug spending and US
drug sales represent ing 48 % of global sales.22

Schemat ic of pharmaceut ical pipeline model.
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Three scenarios are shown, each of which are predicated on a 10 % decrease in revenue f rom t he
baseline.
- Proport ional Cut : This scenario assumes t he number of product s entering phase 1, phase 2, and
phase 3 are each reduced in proport ion to t he reduct ion in R& D expense for companies of dif ferent
size. This result s in a reduct ion in approvals f rom 47 to 45 (4.3% reduct ion).
- Cost reduct ion in late phase t rials: This scenario assumes t hat t he number of product s entering
phase 1 or phase 2 is unchanged, but t he number entering phase 3 was reduced to achieve t he f ull
reduct ion of R& D expense for companies of dif ferent size. This result s in a worst -case scenario wit h
43 drug approvals (8 .6 % reduct ion).
- Cost reduct ion in early phase t rials: This scenario assumes t hat 9 0 % of t he cost reduct ion is
achieved t hrough a proport ional reduct ion in phase 1 or phase 2 t rials. W hile t he number of product s
entering phase 3 decreases, t he ret ained spending for phase 3 is suf f icient to reduce t he commercial
f ailure rate, and t he number of approved product s is unchanged f rom t he baseline case (no reduct ion).
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Fi g u r e 6 :

M odeling t he pharmaceut ical pipeline wit h revenue reduct ions of 10 %

Baseline case

Phase 1 - 40 0 drugs
$25.3 M/drug success rate=60 %

Phase 2 - 238 drugs
$58 .6 M/drug success rate=36%

Phase 3 - 8 5 drugs
$255.4 M/drug success rate=62%

Phase 4 - 47 drugs
success rate=90 %

% reduct ion :

Scenario 1

Scenario 2

Scenario 3

Proportional cost
reduction

Cost reduction in
late phase trials

Cost reduction in
early phase trials

38 4 drugs
4% cost reduction

40 0 drugs
0 % cost reduction

368 drugs
8 % cost reduction

229 drugs
4% cost reduction

238 drugs
0 % cost reduction

224 drugs
6% cost reduction

8 1 drugs
4% cost reduction

77 drugs
8 % cost reduction

8 4 drugs
1% cost reduction

Approved - 45 drugs

Approved - 43 drugs

Approved - 47 drugs

4 .3 %

8 .6 %

0%
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Three scenarios for reducing R& D expense
in response
to a 10
% decrease
in pharmaceut
ical revenue. The model assumes dif ferent levels of
cost reduct ion by companies of dif ferent size and t hat cost reduct ions will be achieved by reduct ion of spending on phased clinical t rials. The
t hree scenarios posit dif ferent ial allocat ion of cost reduct ions bet ween phase 1, phase 2, or phase 3 t rials.

These t hree scenarios demonst rate t he abilit y of large pharmaceut ical companies to mit igate any
impact of drug price reduct ions on t heir product development pipelines t hrough st rategic allocat ion of
cost reduct ions to dif ferent phases of clinical development . The t hree scenarios shown achieve
equivalent reduct ions in R& D spending, but result in reduct ions in t he number of new drug approvals
by 4.3%, 8 .6 %, and 0 % respect ively. It should be emphasized t hat t his model does not posit any
changes in t he process of pharmaceut ical development or regulatory review, but simply agile resource
and asset management .

Our model shows that large companies may mitigate any negative
impact of drug price reductions on pharmaceutical innovation
through agile management and strategic allocation of cost
reductions.
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Conclusions
This analysis suggest s t hat any negat ive impact of drug price reduct ions on t he pipeline of
pharmaceut ical innovat ion may be mit igated t hrough st rategic allocat ion of spending reduct ions in
large pharmaceut ical companies. Policy makers do not need to make a f alse choice bet ween reducing
prices to ensure t he af fordabilit y of pharmaceut ical product s current ly on t he market and t he
innovat ion required to bring new product s to market in t he f ut ure.

Policy makers do not need to make a false choice
between reducing prices to ensure the availability of
pharmaceutical products currently on the market and
the innovation required to bring new products to market
in the future.
This analysis dif fers subst ant ively f rom previous analyses of t he potent ial ef fect s of reducing drug
prices on t he pipeline of pharmaceut ical innovat ion.

- First , t his analysis considersWILL
all public
biotechnology
and
pharmaceut
ical companies ident if ied by
REDUCING
DRUG PRICES
SLOW
INNOVATION
GICS codes listed in Compust at . Previous st udies have focused primarily on limited set s of large
pharmaceut ical companies and have of ten f ailed to address t he cont ribut ions of t he much larger
number of small, early-st age or emerging biopharmaceut ical companies.

- Second, while a small number of large, f ully integrated pharmaceut ical companies are responsible for
t he manuf act ure and market ing of t he great majorit y of product s on t he market , small companies
conduct t he majorit y of all clinical t rials and are increasingly responsible for launching new product s.
This analysis shows t hat approximately 6 0 % of all corporate-sponsored clinical t rials are sponsored by
?small? companies wit h a market capit alizat ion <$7 billion. This observat ion is consistent wit h t he dat a
f rom IQVIA showing t hat t hat up to 70 % of phase 3 t rials and 40 % of all product launches over t he
past f ive years involved small biopharmaceut ical companies (<$50 0 M revenue and <$20 0 R& D).23

- Third, t his analysis recognizes t hat t he f inances of large pharmaceut ical companies wit h robust
revenue and earnings are very dif ferent t han t hose of smaller biopharmaceut ical companies, which
consistent ly report limited revenue and negat ive earnings. This analysis suggest s t hese t wo set s of
companies are likely to have dif ferent st rategic responses to decreasing revenue. W hile t here is a
consistent historical associat ion bet ween revenue and R& D for t he largest pharmaceut ical companies,
no such associat ion was evident for smaller companies.
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These observat ions are not unexpected. The valuat ion of large, f inancialized pharmaceut ical
companies is crit ically dependent on met rics such as earnings per share (EPS). Decreasing R& D
expense in response to reduct ions in revenue is an ef f icient st rategy for sust aining t he level of
earnings and limit ing negat ive impact s on corporate valuat ions. Moreover, large companies are
increasingly focused on t he manuf act ure and market ing of product s acquired t hrough licensing,
merger, or acquisit ion, rat her t han t hose developed t hrough internal R& D.24 McKinsey has est imated
t hat f rom 20 0 1 to 20 16 , t he f ract ion of large pharma revenue coming f rom acquisit ions, rat her t han
internal R& D, grew f rom 25 to 50 percent , and a recent analysis of 14 large pharmaceut ical companies
showed t hat only 40 % of t heir new drug launches originated f rom internal R& D. Given t his increasing
focus on product acquisit ion, analyst s expect at ions for f ut ure revenue may not be signif icant ly
impacted by decreasing R& D in response to reduct ions in drug prices and revenue.

In cont rast , smaller pharmaceut ical companies of ten have science-based business models t hat focus
on advancing and validat ing plat form technologies or innovat ive t herapeut ics, which are later acquired
by larger companies t hrough licensing agreement s or corporate acquisit ion. Since t hese companies
t ypically have lit t le revenue and negat ive earnings, current earnings are largely irrelevant to company
valuat ions, which are based largely on analyst s?expect at ions for f ut ure revenue and earnings. Thus,
small companies are likely to priorit ize R& D spending in response to decreases in revenue. W hile small
WILL
DRUGyPRICES
SLOW
INNOVATION
companies are of ten dependent
onREDUCING
t he availabilit
of capit
al invest
ment s, we are not aware of

empirical evidence t hat reduct ions in drug prices would adversely impact invest ment s in early-st age or
emerging biotechnology companies.14 In f act , t he increasing reliance of large pharmaceut ical
companies on early and emerging biotechnology companies for innovat ion is already a major driver of
innovat ion and valuat ion in t he biotechnology sector. These forces may become even more
pronounced if large pharmaceut ical companies reduce t heir R& D spending and t urn increasingly to
merger and acquisit ion.25

- Finally, previous analyses have f ailed to consider t he abilit y of t he pharmaceut ical indust ry to
st rategically respond to reduct ion in R& D spending to preserve t he pipeline of pharmaceut ical
innovat ion. Decades of management reform in t he pharmaceut ical indust ry has focused on
implement ing ?agile? management systems t hat provide companies wit h subst ant ial f lexibilit y to
respond to changing circumst ances and opport unit ies, mit igat ing risks, and opt imizing asset
ut ilizat ion.26 Agile management pract ices are evident in t he longst anding t rend towards out sourcing
clinical development and t he progressive eliminat ion of operat ional const raint s embodied in t radit ional
f acilit ies, governance, communicat ions, supply chains, and employment pract ices. The st rategic
reallocat ion of resources to dif ferent phases of clinical development would be a classic applicat ion of
agile management pract ice.
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This analysis shows t hat price reduct ions ant icipated f rom t he proposed legislat ion, if properly
managed, could have minimal impact on pharmaceut ical innovat ion and t he emergence of new
product s for prevent ion, t reat ment , and regenerat ion. We would emphasize t hat t his conclusion is
based squarely on current best pract ices in t he biopharmaceut ical indust ry, t he observed relat ionship
bet ween revenue and R& D spending over t he past t wo decades, and t he cont ribut ions current ly being
made to pharmaceut ical innovat ion by companies of dif ferent size.

Best practices of biopharmaceutical finance and management are
sufficiently robust to provide patients with relief from drug prices
that make essential medicines unaffordable without inhibiting
development of innovative new products for prevention, treatment,
and regeneration.
This model is not aspirat ional; it does not presume changes in t he process, f inancing, or regulat ion of
pharmaceut ical innovat ion, it does not post ulate t hat advances in informat ion technology or research
pract ices will improve R& D ef f iciency, and it does not require changes to t he business models of
pharmaceut ical companies or a repriorit izat ion of pat ient s and social responsibilit y over shareholders
and prof it . Rat her, t his analysis
suggest
s t hatDRUG
best PRICES
pract ices
of INNOVATION
biopharmaceut ical f inance and
WILL
REDUCING
SLOW
management are suf f icient ly robust to provide pat ient s wit h relief f rom drug prices t hat make
essent ial medicines unaf fordable wit hout inhibit ing development of innovat ive new product s for
prevent ion, t reat ment , and regenerat ion.
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At t achment s
At t achment 1. Financial t ot als f or large and small pharmaceut ical companies
20 0 0 -20 18
ALL
# f iscal years (N) 10 ,0 35
# companies (N)

1,379

Large Companies a Small Companiesb
6 18 c

9 ,417 d

78 c

1,30 1

( $ , billions 20 0 0 - 20 18 )
Revenue $12,0 6 6

$11,38 5

$6 8 1

Sale of Common and Preferred St ock

$50 3

$212

$29 0

Cost s of Goods Sold

$3,140

$2,70 3

$436

R& D

$2,0 19

$1,737

$28 1

Gross Prof it

$8 ,9 26

$8 ,6 8 1

$244

EBITDA (Loss) $3,577

$3,6 72

-$9 4

Net Income (Loss) $1,59 6

$1,8 58

-$26 2

Income
Taxes DRUG
$549PRICES SLOW $540
WILL REDUCING
INNOVATION

$8 .8 7

Dividends

$9 79

$9 6 4

$14.5

Purchase of Common and Preferred
St ock

$79 3

$773

$19 .3

a Large

companies are def ined as having a market capit alizat ion >$7 billion in a f iscal year; b Small companies are def ined as

having a market capit alizat ion <$7 billion in a f iscal year; c Number of f iscal years wit h market capit alizat ion >$ 7 billion; d
Number of f iscal years wit h market capit alizat ion <$7 billion; e Number of companies wit h at least one f iscal year wit h market
capit alizat ion >$7 billion. Tot als are shown for t he years 20 0 0 -20 18 . All dat a are f rom Compust at and are inf lat ion adjusted to
20 18 .
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At t achment 2. M edian and Int erquart ile range of f inancial met rics f or large and
small biopharmaceut ical companies.
Small Companiesa

Large Companiesa

M edian (IQR) ($ millions)

M edian (IQR) ($ millions)

111.2 (27.7 to 39 0 .7)

40 ,39 9 (13,6 6 9 to 10 1,0 33)

3.1 (0 .0 to 27.5)

9 ,550 (2,9 13 to 28 ,578 )

preferred st ock

5.4 (0 .3 to 29 .8 )

10 6 .2 (25.2 to 347.5)

R& Dd

12.5 (2.5 to 34.7)

1,513.4 (447.6 to 4,521.8 )

0 (-16 .6 to 4.3)

7,233.6 (1,8 8 8 to 22,454)

-12.1 (-32.5 to 2.1)

3,0 23 (79 6 .5 to 9 ,117)

-14.4 (-37.8 to -2.8 )

1,150 (258 .2 to 4,713)

market capit alizat ion c
revenue
sale of common and

gross prof it
EDITDA
net income

research int ensit y e
net income
a Small

2.8 (0 .4 to 121.3)

margin fWILL REDUCING DRUG PRICES SLOW
-5.1 (-56 2.2 to -0 .5)

0 .17 (0 .13 to 0 .22)
INNOVATION

0 .15 (0 .0 6 to 0 .21)

companies are def ined as having a market capit alizat ion <$7 billion in a f iscal year; b Large companies are def ined as

having a market capit alizat ion >$7 billion in a f iscal year; c Calculated f rom stock price and common shares out st anding; d
Calculated wit hout in-process R& D; e Calculated as R& D/revenue; f Calculated as net income/revenue. All dat a are f rom
Compust at and are inf lat ion adjusted to 20 18 .
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ically, (i) t he model uses upper bound

values for t he likely reduct ion in R& D expense for each quart ile of large companies; (ii) clinical t rials involving mult iple companies are assigned to t he largest company, which exhibit t he great est reduct ion
in R& D expense; (iii) t his model assumes t hat reduct ions in R& D will be achieved exclusively by decreasing t he number of compounds in clinical t rials and does not contemplate innovat ions t hat might
increase t he eff iciency of pharmaceut ical R& D; (iv) t he result shown ref lect s t he steady st age level of
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broad terms, an agile organization
is one thatDRUG
combines
stable
backbone of core processes and ca-

pabilities with a high degree of flexibility for rapid response to change.?

Limit at ions: There are import ant limit at ions to t his work. First , t his analysis focuses explicit ly on corporate f inancial dat a reported in accordance wit h U.S. GAAP st andards and reported to t he SEC. Financial account ing met rics do not necessarily ref lect cash f lows in any given f iscal year and have technical def init ions t hat are not synonymous wit h t heir colloquial meanings. Specifically, R& D ?expense? in
a f iscal year is not synonymous wit h R& D spending in t hat year, and may not include t he cost s of f acilit ies, equipment , ot her asset s (including approved product s), or t he upf ront cost s of research part nerships t hat may be capit alized and depreciated over t ime. Similarly, ?revenue? does not include t he proceeds f rom capit al invest ment s (e.g., stock sales). These met rics, nevert heless, represent crit ical
benchmarks for corporate st rat egy and performance, and are designed to enable greater t ransparency, consistency, and comparabilit y across companies. Second, t his analysis focuses explicit ly on
revenue accrued by biopharmaceut ical companies, which is only indirect ly related to t he list price or
t he sale price of pharmaceut ical product s due to t he layered nat ure of t he pharmaceut ical dist ribut ion
system. (Sood N., Shih, T., Van Nuys, K. & Goldman, D., 20 17. The Flow of Money Through t he Pharmaceut ical Dist ribut ion System. USC Leonard D. Schaeffer Center for Health Policy & Economics.
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ht t ps://healt hpolicy.usc.edu/research/f low-of -money-t hrough-t he-pharmaceut ical-dist ribut ionsystem/; Yu, N.L., At teberry, P. & Bach, P.B., 20 18 . Spending on prescript ion drugs in t he US: where
does all t he money go? Health Affairs Blog. ht t ps://www.healt haf f airs.org/do/10 .1377/hblog20 18 0 726 .6 70 59 3/f ull/; Duset zina, S.B. & Bach, P.B., 20 19 . Prescript ion
drugs? list price, net price, and t he rebate caught in t he middle. JAMA, 321(16 ) pp.156 3-156 4.
doi:10 .10 0 1/jama.20 19 .2445. ht t ps://pubmed.ncbi.nlm.nih.gov/30 8 40 0 47/.) Third, f urt her research is
required on t he f low of capit al f rom drug sales by large pharmaceut ical companies, which manuf act ure
and market t he large majorit y of pharmaceut ical product s, to small biopharmaceut ical companies or
t heir investors, which are responsible for an increasing share of clinical t rials and drug launches. It is
likely t hat much of t his value is embodied in t he premiums paid for licenses or acquisit ions, and lit t le
empirical evidence as to how such premiums would be impacted by reducing drug prices . Fourth, a
more nuanced model of t he pharmaceut ical pipeline is required t hat account s for bot h t he t imelines of
product development and t he dynamic f lux of product s bet ween large and small pharmaceut ical companies. It is likely t hat such models will reveal even greater opport unit ies for agile management to
compensate for reduct ions in revenue wit hout limit ing t he out put of new product s. Finally, t his analysis
was limited to t he impact of revenue reduct ions up to 10 %, ref lect ing t he boundary of t he dat a used to
generate t he model. There is no empirical dat a on which to base est imates of t he relat ionship bet ween
R& D expense and reduct ions of revenue >10 %.
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